One or more of the required application components couldn’t be loaded. Please, refresh the page.
HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsPricing
8:05 AM
Theme 		Help

NEW: Premarket Now Starts at 4AM!

We’re excited to announce the extension of premarket and aftermarket hours! Our members now have access to quotes daily from 4:00 AM to 8:00 PM ET — offering greater flexibility and deeper insights into market trends beyond regular trading hours.

Upgrade to FINVIZ*Elite to access premarket quotes »

NTHI

NeOnc Technologies Holdings Inc

Last Close
Apr 17 • 04:00PM ET
6.95
Dollar change
-0.05
Percentage change
-0.71 		%
Healthcare • Biotechnology • USA • NASD
Peers: MRNA BNTX FATE INO NVAX VXRT AGEN ARCT CLOV
Scroll to Statements
Index- P/E- EPS (ttm)- Insider Own79.45% Shs Outstand20.36M Perf Week-22.78%
Market Cap130.31M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float3.85M Perf Month-
Income- PEG- EPS next Q- Inst Own- Short Float0.18% Perf Quarter-
Sales- P/S- EPS this Y- Inst Trans- Short Ratio0.11 Perf Half Y-
Book/sh- P/B- EPS next Y- ROA- Short Interest0.01M Perf Year-
Cash/sh- P/C- EPS next 5Y- ROE- 52W Range6.10 - 25.00 Perf YTD-42.61%
Dividend Est.- P/FCF- EPS past 5Y- ROI- 52W High-72.20% Beta-
Dividend TTM- Quick Ratio- Sales past 5Y- Gross Margin- 52W Low13.93% ATR (14)3.70
Dividend Ex-Date- Current Ratio- EPS Y/Y TTM- Oper. Margin- RSI (14)- Volatility16.59% -
Employees- Debt/Eq- Sales Y/Y TTM- Profit Margin- Recom- Target Price-
Option/ShortNo / Yes LT Debt/Eq- EPS Q/Q- Payout- Rel Volume0.33 Prev Close7.00
Sales Surprise- EPS Surprise- Sales Q/Q- Earnings- Avg Volume59.95K Price6.95
SMA20-31.06% SMA50-31.06% SMA200-31.06% Trades Volume20,451 Change-0.71%
Apr-15-25 08:05AM
NeOnc Technologies Global Patent Portfolio Covers Core Pipeline Across All Major Pharmaceutical Markets
(GlobeNewswire)
Apr-14-25 08:05AM
NeOnc Technologies Holdings, Inc. Expects Full Enrollment in Promising Phase 2a Trial of NEO100-01 for Malignant Gliomas in September
(GlobeNewswire) -12.06%
Apr-10-25 08:05AM
NeOnc Technologies Holdings, Inc. Executive Chairman, Amir Heshmatpour, Assumes Expanded Leadership Role as Company's New President
(GlobeNewswire) -10.00%
Apr-08-25 04:05PM
NeOnc Technologies Announces Near Completion of Phase I Enrollment for NEO212 Brain Cancer Therapy
(GlobeNewswire)
Mar-31-25 08:05AM
NeOnc Technologies Holdings, Inc. Receives Rare Pediatric Disease Designation for NEO100 in Treatment of Pediatric-Type Diffuse High-Grade Gliomas
(GlobeNewswire) -19.27%
11:15PM Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.Finviz Elite
Mar-28-25 11:15PM
U.S. IPO Weekly Recap: CoreWeave Fails To Impress In Downsized IPO, As More Names Join The Pipeline
(Seeking Alpha) +37.92%
Mar-27-25 08:05AM
NeOnc Technologies Expands Global Clinical Trial Network with CBCC Global Research to Accelerate Study of Brain Cancer Treatments
(GlobeNewswire)
NeOnc Technologies Holdings, Inc. is a clinical-stage biopharmaceutical company. It develops novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. The company was founded in 2008 and is headquartered in Calabasas, CA.
open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR
affiliate • advertise • theme settings • contact • help • privacy • do not sell my data
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2025 FINVIZ.com. All Rights Reserved.